SCHEMBL25425822

SCHEMBL25425822

CCn1cc(-c2ccn3c(-c4ccc(-c5noc(C)n5)cc4)cnc3c2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 12/20 0.45
KDR P35968 2/20 0.42
NEK2 P51955 3/20 0.40
ABL1 P00519 1/20 0.40
PDGFRA P16234 1/20 0.40
CSK P41240 1/20 0.40
SIK1 P57059 1/20 0.40
IKBKE Q14164 1/20 0.40
SIK2 Q9H0K1 1/20 0.40
TBK1 Q9UHD2 1/20 0.40
TNIK Q9UKE5 1/20 0.40
SIK3 Q9Y2K2 1/20 0.40
AURKA O14965 1/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PI4KA P42356 1/20 0.38
PIK3CG P48736 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
FGFR3 P22607 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27030682 0.81 FGFR3 (0.48) FLT3KDRNEK2ABL1PDGFRA
SCHEMBL25425217 0.79 FLT3 (0.50) FLT3KDRNEK2ABL1PDGFRA
SCHEMBL27030611 0.75 FLT3 (0.49) FLT3KDRNEK2ABL1PDGFRA
SCHEMBL30775112 0.75 FLT3 (0.49) FLT3KDRNEK2ABL1PDGFRA
SCHEMBL27030692 0.74 FLT3 (0.47) FLT3KDRNEK2ABL1PDGFRA
SCHEMBL27046556 0.71 FLT3 (0.36) FLT3KDRPIK3CAPIK3CBFGFR3
SCHEMBL25426963 0.66 ABL1 (0.72) FLT3NEK2ABL1PDGFRACSK
SCHEMBL31386948 0.66 FLT3 (0.77) FLT3KDRNEK2ABL1PDGFRA
SCHEMBL7226136 0.65 L3MBTL1 (0.56) FLT3KDR
SCHEMBL25298743 0.65 PIK3CD (0.43) KDRABL1SIK1SIK2SIK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 US disclosed
EP-4660192-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2025-12-10 EP disclosed
WO-2024233967-A2 SIK INHIBITORS TO TREAT CHRONIC KIDNEY DISEASE THE GENERAL HOSPITAL CORPORATION (US) 2024-11-14 WO disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
EP-4192459-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2023-06-14 EP disclosed
CN-116234549-A Salt-induced kinase inhibitors 总医院公司 2023-06-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 FLT3 2994/4885KDR 1018/4885NEK2 67/4885
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS SGK1, SGK2, SIK1 FLT3 1688/4885KDR 2083/4885NEK2 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.